Photo from wikipedia
Acalabrutinib, a selective Bruton tyrosine kinase inhibitor, is approved for the treatment of mantle cell lymphoma and chronic lymphocytic leukaemia. Many critically ill patients are unable to swallow and need… Click to show full abstract
Acalabrutinib, a selective Bruton tyrosine kinase inhibitor, is approved for the treatment of mantle cell lymphoma and chronic lymphocytic leukaemia. Many critically ill patients are unable to swallow and need oral medications to be delivered via a nasogastric (NG) tube. Furthermore, critically ill patients are typically administered proton‐pump inhibitors (PPIs) to prevent stress ulcers. Concomitant administration with PPIs reduces acalabrutinib exposure and is not currently recommended. To evaluate acalabrutinib in subjects co‐administered with PPIs who require NG delivery, a phase 1, open‐label, randomized, crossover, single‐dose study was conducted in healthy subjects.
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!